Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Johan Indra Lukito
Medical Department, PT Kalbe Farma Tbk., Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Antidiabetik Oral Kombinasi Penghambat DPP-4 dan Penghambat SGLT-2 Johan Indra Lukito
Cermin Dunia Kedokteran Vol 48, No 12 (2021): General Medicine
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v48i12.1572

Abstract

Dalam tatalaksana diabetes melitus tipe 2, terapi kombinasi dua obat antidiabetik disarankan jika dengan monoterapi gagal mencapai target kontrol glikemik. Pemilihan jenis obat antidiabetik tergantung kondisi pasien dan profil obat. Kombinasi obat antidiabetik oral golongan penghambat DPP-4 (dipeptidyl peptidase-4) dan penghambat SGLT-2 (sodium-glucose cotransporter type 2) dapat menjadi salah satu pilihan.Combination of two antidiabetic drugs is recommended in the management of type 2 diabetes mellitus if monotherapy fails to achieve glycemic control targets. Choice of antidiabetic drugs depends on the patient's condition and drugs’ profile. Combination of oral antidiabetic drugs DPP-4 (dipeptidyl peptidase-4) class and SGLT-2 (sodium-glucose cotransporter type 2) inhibitors can be an option.
Antidiabetik Oral Kombinasi Penghambat DPP-4 dan Penghambat SGLT-2 Johan Indra Lukito
Cermin Dunia Kedokteran Vol 48 No 12 (2021): Penyakit Dalam
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v48i12.157

Abstract

Dalam tatalaksana diabetes melitus tipe 2, terapi kombinasi dua obat antidiabetik disarankan jika dengan monoterapi gagal mencapai target kontrol glikemik. Pemilihan jenis obat antidiabetik tergantung kondisi pasien dan profil obat. Kombinasi obat antidiabetik oral golongan penghambat DPP-4 (dipeptidyl peptidase-4) dan penghambat SGLT-2 (sodium-glucose cotransporter type 2) dapat menjadi salah satu pilihan. Combination of two antidiabetic drugs is recommended in the management of type 2 diabetes mellitus if monotherapy fails to achieve glycemic control targets. Choice of antidiabetic drugs depends on the patient's condition and drugs’ profile. Combination of oral antidiabetic drugs DPP-4 (dipeptidyl peptidase-4) class and SGLT-2 (sodium-glucose cotransporter type 2) inhibitors can be an option.
Antidiabetik Oral Kombinasi Penghambat DPP-4 dan Penghambat SGLT-2 Johan Indra Lukito
Cermin Dunia Kedokteran Vol 48 No 12 (2021): Penyakit Dalam
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v48i12.157

Abstract

Dalam tatalaksana diabetes melitus tipe 2, terapi kombinasi dua obat antidiabetik disarankan jika dengan monoterapi gagal mencapai target kontrol glikemik. Pemilihan jenis obat antidiabetik tergantung kondisi pasien dan profil obat. Kombinasi obat antidiabetik oral golongan penghambat DPP-4 (dipeptidyl peptidase-4) dan penghambat SGLT-2 (sodium-glucose cotransporter type 2) dapat menjadi salah satu pilihan. Combination of two antidiabetic drugs is recommended in the management of type 2 diabetes mellitus if monotherapy fails to achieve glycemic control targets. Choice of antidiabetic drugs depends on the patient's condition and drugs’ profile. Combination of oral antidiabetic drugs DPP-4 (dipeptidyl peptidase-4) class and SGLT-2 (sodium-glucose cotransporter type 2) inhibitors can be an option.
Co-Authors